5. CONCLUSION
In conclusion, our findings demonstrated that IL-10 is a potential
target for the treatment of SFTSV and SARS-CoV-2-related
immunopathology.
Therefore, blockade of IL-10 signalling using monoclonal antibodies
against the IL-10 receptor is a promising therapeutic for treating fatal
SFTS and severe and critically ill COVID-19
patients.[7, 10]